Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Allergan Issues Voluntary Nationwide Recall in the U.S. of Specific Lots of REFRESH® Lacri-Lube®, REFRESH P.M. ®, FML® (fluorometholone ophthalmic ointment) 0.1%, and Blephamide® (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% for Particulate Matter


News provided by

Allergan plc

Aug 24, 2015, 08:35 ET

Share this article

Share toX

Share this article

Share toX

DUBLIN, Aug. 24, 2015 /PRNewswire/ -- Allergan plc, today announced that it is conducting a voluntary recall down to consumer level of specific lots of its REFRESH® Lacri-Lube® 3.5g and 7g  for dry eye, REFRESH P.M.® 3.5g for dry eye, FML® (fluorometholone ophthalmic ointment) 0.1% (sterile ophthalmic ointment topical anti-inflammatory agent for ophthalmic use, 3.5g), and Blephamide® (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% sterile topical ophthalmic ointment combining an antibacterial and a corticosteroid, 3.5g. 

Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO

Allergan chose to initiate this recall based on a small number of customer complaints which reported a small black particle at the time of use. This black particle, which is part of the cap, can be created by the action from unscrewing the cap of the aluminum tube, and potentially introduced into the product. Reported adverse events include Foreign Body in Eye (12), Eye Irritation (2), Ocular Discomfort (2), Product Contamination (2), Superficial Injury of Eye (2), Eye Pain (1), Eye Swelling (1) and Vision Blurred (1).

Specific lots are being voluntarily recalled in the interest of patient safety. If the particle gets into the eye, potential adverse events may include eye pain, eye swelling, ocular discomfort or eye irritation. Please contact your physician or healthcare provider if you have any of these symptoms when using these products. The lot number and expiration date may be found on the bottom flap of the carton with the safety seal and on the crimp seal of the product tube.

Specific information on product and lots that are being voluntarily recalled are below

NDC

Description

Lot Number

Expiration Date

0023-0312-04

REFRESH® Lacri-Lube® 3.5 g

84746

Apr-17

0023-0312-04

REFRESH® Lacri-Lube® 3.5 g

84987

May-17

0023-0312-04

REFRESH® Lacri-Lube® 3.5 g

85087

May-17

0023-0312-04

REFRESH® Lacri-Lube® 3.5 g

85359

Jun-17

0023-0312-04

REFRESH® Lacri-Lube® 3.5 g

85721

Jul-17

0023-0312-04

REFRESH® Lacri-Lube® 3.5 g

86045

Aug-17

0023-0312-04

REFRESH® Lacri-Lube® 3.5 g

86406

Sep-17

0023-0312-04

REFRESH® Lacri-Lube® 3.5 g

86594

Oct-17

0023-0312-04

REFRESH® Lacri-Lube® 3.5 g

87021

Nov-17

0023-0312-07

REFRESH® Lacri-Lube® 7g

86470

Sep-17

0023-0312-07

REFRESH® Lacri-Lube® 7g

86829

Oct-17

0023-0312-07

REFRESH® Lacri-Lube® 7g

87105

Nov-17

0023-0240-04

REFRESH P.M.® 3.5 g

85165

May-17

0023-0240-04

REFRESH P.M.® 3.5 g

85228

May-17

0023-0240-04

REFRESH P.M.® 3.5 g

85244

Jun-17

0023-0240-04

REFRESH P.M.® 3.5 g

85351

Jun-17

0023-0240-04

REFRESH P.M.® 3.5 g

85374

Jun-17

0023-0240-04

REFRESH P.M.® 3.5 g

85397

Jun-17

0023-0240-04

REFRESH P.M.® 3.5 g

85561

Jul-17

0023-0240-04

REFRESH P.M.® 3.5 g

85676

Jul-17

0023-0240-04

REFRESH P.M.® 3.5 g

85694

Jul-17

0023-0240-04

REFRESH P.M.® 3.5 g

85834

Aug-17

0023-0240-04

REFRESH P.M.® 3.5 g

85977

Aug-17

0023-0240-04

REFRESH P.M.® 3.5 g

85985

Aug-17

0023-0240-04

REFRESH P.M.® 3.5 g

86073

Aug-17

0023-0240-04

REFRESH P.M.® 3.5 g

85599

Sep-17

0023-0240-04

REFRESH P.M.® 3.5 g

86290

Sep-17

0023-0240-04

REFRESH P.M.® 3.5 g

86325

Sep-17

0023-0240-04

REFRESH P.M.® 3.5 g

86411

Sep-17

0023-0240-04

REFRESH P.M.® 3.5 g

86427

Sep-17

0023-0240-04

REFRESH P.M.® 3.5 g

86506

Sep-17

0023-0240-04

REFRESH P.M.® 3.5 g

86515

Sep-17

0023-0240-04

REFRESH P.M.® 3.5 g

86517

Sep-17

0023-0240-04

REFRESH P.M.® 3.5 g

86746

Oct-17

0023-0240-04

REFRESH P.M.® 3.5 g

86792

Oct-17

0023-0240-04

REFRESH P.M.® 3.5 g

86789

Oct-17

0023-0240-04

REFRESH P.M.® 3.5 g

86809

Oct-17

0023-0240-04

REFRESH P.M.® 3.5 g

86822

Oct-17

0023-0240-04

REFRESH P.M.® 3.5 g

86822A

Oct-17

0023-0240-04

REFRESH P.M.® 3.5 g

86932

Nov-17

0023-0240-04

REFRESH P.M.® 3.5 g

87100

Nov-17

0023-0240-04

REFRESH P.M.® 3.5 g

87068

Nov-17

0023-0240-04

REFRESH P.M.® 3.5 g

87156

Dec-17

0023-0240-04

REFRESH P.M.® 3.5 g

87261

Dec-17

0023-0240-04

REFRESH P.M.® 3.5 g

87493

Jan-18

0023-0240-04

REFRESH P.M.® 3.5 g

87494

Feb-18

0023-0240-04

REFRESH P.M.® 3.5 g

87731

Feb-18

0023-0240-04

REFRESH P.M.® 3.5 g  (Professional
Sample Pack)

85165

May-17

0023-0240-04

REFRESH P.M.® 3.5 g (Professional
Sample Pack)

86789

Oct-17

0023-0316-04

FML® (fluorometholone ophthalmic
ointment) 0.1%, 3.5 g

86258

Sep-17

0023-0316-04

FML® (fluorometholone ophthalmic
ointment) 0.1%, 3.5 g

87189

Dec-17

0023-0316-04

FML® (fluorometholone ophthalmic
ointment) 0.1%, 3.5 g

87514

Feb-18

0023-0313-04

Blephamide® (sulfacetamide sodium and
prednisolone acetate ophthalmic ointment, USP) 10%/0.2%, 3.5 g

86430

Sep-17

0023-0313-04

Blephamide® (sulfacetamide sodium and
prednisolone acetate ophthalmic ointment, USP) 10%/0.2%, 3.5 g

87806

Feb-18

0023-0313-04

Blephamide® (sulfacetamide sodium and
prednisolone acetate ophthalmic ointment, USP) 10%/0.2%, 3.5 g

88147

Mar-18

Allergan has informed the U.S. Food and Drug Administration of this voluntary recall. The recall only applies to specific lots of the REFRESH® Lacri-Lube®, REFRESH P.M. ®, FML® (fluorometholone ophthalmic ointment) 0.1%, Blephamide® (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2%. This recall does not affect any other REFRESH or Allergan product.  

Allergan is contacting retailers and wholesalers who have been shipped affected product lots to initiate the recall and is informing them of the steps needed to return affected product.

The company is asking consumers who currently have product from any of the affected  lots of REFRESH® Lacri-Lube®, REFRESH P.M. ®, FML® (fluorometholone ophthalmic ointment) 0.1% , Blephamide® (sulfacetamide sodium or prednisolone acetate ophthalmic ointment, USP) 10%/0.2%, to stop using the product and return it to Allergan.

If there are questions or if assistance is required in response to this recall, please use the contact information below.

CONTACT INFORMATION

Product Returns

Contact GENCO at:

877-674-2087

7 am to 5 pm CST

Credit/Reimbursements

Contact Allergan at:

1-800-811-4148

7am to 5pm PST

Allergan

Medical Inquiries:

1-800-433-8871 option 2 8am - 5pm PST

Adverse Events/Product Complaints:

1-800-624-4261 Option 3 (8am – 5pm CST

FDA contact information for reporting adverse events/quality complaints:

Online at www.fda.gov/medwatch/report.htm or call FDA at 1-800-FDA-1088

Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to the use of this product.

CONTACTS:

Investors:
Lisa DeFrancesco
(862) 261-7152

Media:
Mark Marmur
(973) 906-1526

SOURCE Allergan plc

Related Links

http://www.actavis.com

21%

more press release views with 
Request a Demo

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.